Vol. 01 · Issue 002
Australia's Consumer Health Trend
March – May 2026
NMN goes mainstream, private label surges, GLP-1 adjacency deepens, TGA Andrographis watch
2 May 2026
20 confirmed and emerging commercial signals across 6 categories — NMN sponsor exclusivity expiring and driving mainstream CWH entry, private label supplements reaching record consumer trust, Andrographis facing TGA removal consultation, semaglutide eligibility at 39.7% creating an unprecedented adjacent-category opportunity, and pharmacy-led beauty brands accelerating their derma crossover.
Issue Highlights
- NMN exclusivity ends — CWH mainstream entry Q2 2026
- Private label supplements: 74% consumer trust milestone
- Andrographis TGA removal consultation — OTC cold shelf at risk
- 39.7% Australians GLP-1 eligible — adjacent category surge
- CeraCare collagen+ positioned as pharmacy skin-barrier leader
- Melatonin rescheduled: OTC sleep category expands
Read Full Issue →
~20 min read